Well, it's still a big plus that they're willing to work with ENZC! :) If ENZC can ever get its product to market, manufacturing shouldn't be a hurdle. Better than routing thru a smaller lab in Bulgaria. (And no offense to partners like Rosetta; but Samsung is objectively better for worldwide mass production.)
The ball is still in ENZC's court to actually deliver on a viable drug.
Market Data 
Markets 
AI
